Sugi Predict
/ Targets
/ MSH2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to MSH2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer |
PHASE4 | UNKNOWN |
| mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC |
PHASE3 | RECRUITING |
| Real-world Trial of Individualized Precision Oncology |
PHASE2 | NOT_YET_RECRUITING |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) |
PHASE1/PHASE2 | RECRUITING |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) |
PHASE2 | COMPLETED |
| A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI. |
PHASE2 | NOT_YET_RECRUITING |
| Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) |
PHASE2 | RECRUITING |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG |
PHASE2 | NOT_YET_RECRUITING |
| Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) |
PHASE2 | NOT_YET_RECRUITING |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects |
PHASE2 | COMPLETED |
| Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial |
PHASE2 | RECRUITING |
| CHROENDOHNPCC: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer Syndrome |
PHASE2 | COMPLETED |
| A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome |
PHASE2 | RECRUITING |
| Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
PHASE2 | COMPLETED |
| mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC |
PHASE2 | COMPLETED |
| Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome |
PHASE1 | COMPLETED |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study |
PHASE1 | WITHDRAWN |
| Videocapsule Endoscopy in Lynch Syndrome |
nan | RECRUITING |
| Current Microsatellite Stability Results in Colon Cancer |
nan | NOT_YET_RECRUITING |
| Lynch Syndrome in Colorectal Cancer Surgery |
nan | NOT_YET_RECRUITING |
| Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam |
nan | NOT_YET_RECRUITING |
| Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer |
nan | COMPLETED |
| ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes) |
nan | NOT_YET_RECRUITING |
| How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer |
nan | RECRUITING |
| Pancreatic Cancer Early Detection Consortium |
nan | RECRUITING |
| Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer |
nan | WITHDRAWN |
| Inherited Cancer Early Diagnosis (ICED) Study |
nan | UNKNOWN |
| Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer |
nan | RECRUITING |
| Influence of the Surgical Technique Used for Colectomies on the Concentration of Circulating Tumor DNA and the Presence of Circulating Tumor Cells: Comparison of the no Touch Technic With Either First Clamping of the Mesenteric Vessels or First Mobilization of the Tumor Followed by Clamping. |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a MSH2 binder may also engage these)